Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis | Zendy

Jiao Yurui | Zendy; Chen Chenglong | Zendy; Hu Xijian | Zendy; Feng Xu | Zendy; Shi Zhenqi | Zendy; Cao Jie | Zendy; Li Qing | Zendy; Zhu Yikun | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Niclosamide and its derivative DK‐520 inhibit RANKL‐induced osteoclastogenesis

Author(s) -

Jiao Yurui,

Chen Chenglong,

Hu Xijian,

Feng Xu,

Shi Zhenqi,

Cao Jie,

Li Qing,

Zhu Yikun

Publication year - 2020

Publication title -

febs open bio

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.718

H-Index - 31

ISSN - 2211-5463

DOI - 10.1002/2211-5463.12921

Subject(s) - rankl , niclosamide , osteoclast , chemistry , activator (genetics) , mapk/erk pathway , pharmacology , microbiology and biotechnology , cancer research , biochemistry , receptor , kinase , biology , ecology

DK‐520 is an acyl derivative of Niclosamide that exhibits a significant increase in both the plasma concentration and bioavailability. Like Niclosamide, DK‐520 effectively inhibits the early stages of RANKL‐induced osteoclastogenesis and may be a promising drug candidate for treatment of osteoclast‐related diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research